ARGX (argenx.com) Market Value to Book Value Ratio
A bet on elite immunologists and research freedom drives growth that highlights the relationship between the current market price of argenx SE and its net asset value. The value of 6.44 captures the magnitude of this parameter. The business's resilience to crises ensures stability, while strategic technological alliances for antibody licensing rather than acquisitions define the development vector of argenx SE.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_ARGX_-_argenx-SE_-_Market-Capitalization-to-Net-Assets "ARGX argenx BVBA Market Capitalization to Book Value Ratio (07/04/2022 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for argenx N.V. (ARGX)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:argenx SE - ARGX
This ratio reflects the premium of the company's market value over its net assets, allowing investors to assess whether assets are overpriced or the business is undervalued. By analyzing the changes in the P/B ratio of argenx SE (ARGX) on GURU.Markets, one can see how the market capitalizes the scientific potential of argenx SE in the field of antibodies, transforming fundamental research into the high market value of a high-tech business.
Main competitors
Market Cap to Net Assets Ratio BioNTech SE|ABVX (ABIVAX) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio ADMA Biologics, Inc. ADMA|Market Capitalization to Net Assets Protagonist Therapeutics, Inc.|Immunovant Corp (IMVT) - Market Capitalization to Book Value Ratio|Market Value to Book Value Kiniksa Corp (KNSA)|Market Capitalization to Book Value Ratio GRFS (Grifols, S.A.)|adaptivebiotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Celldex Therapeutics, Inc. (CLDX)|AUPH: Market Value to Book Value|BCRX (BioCryst Pharmaceuticals Inc) - Market Value to Book Value Ratio|Vera Corp (VERA) - Market Cap to Net Assets Ratio|DNTH (Dianthus Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pharvaris.com (PHVS)|AbCellera Bio (ABCL) - Market Cap to Net Assets Ratio|Market Value to Book Value Tourmaline Bio Inc (TRML)|Market Capitalization to Book Value Ratio PGEN|Pharming Corp - Market Capitalization to Book Value|NKTR: Market Value to Book Value Ratio|UPB: Market Cap to Net Assets Ratio|ZBIO (Zenas Biopharma) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|GOSS (Gossamer Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|AnaptysBio Corp - Market Capitalization to Book Value Ratio|ATXS: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio enGene Holdings Inc. ENGN|rapt.com (RAPT) - Market Value to Book Value|Aerovate Therapeutics, Inc. - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Aclaris Therapeutics Inc.|Kyverna - Market Capitalization to Book Value Ratio|Market-to-Book Ratio TLSA (Tiziana Life Sciences, Ltd.)|CABA - Market Value to Book Value Ratio|VTYX - Capitalization to Book Value Ratio|Theratechnologies (THTX) - Market Cap to Net Assets Ratio|Avalo Therapeutics, Inc. (AVTX) - Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Eledon ELDN|AGEN (Agenus, Inc) - Market Value to Book Value|CLYM: Market Value to Book Value Ratio|Market Capitalization to Book Value zurabio.com|aTyr Pharma - Market Capitalization to Book Value Ratio|Market-to-Book Ratio adagene.com (ADAG)|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Shattuck Labs Inc - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Equillium Bio (EQ)|CNTB - Market Value to Book Value|Market Capitalization to Book Value Ratio IMUX (immunic-therapeutics.com)|Market Value to Equity Ratio Atara Bio|Market Cap to Net Assets Ratio InflaRx NV (IFRX)|Capitalization to Book Value Ratio XFOR|ACET - Market Value to Book Value Ratio|Market Capitalization to Net Assets celularity.com (CELU)|Market Capitalization to Book Value Ratio INmune Bio|Market Value to Book Value Barinthus Biotherapeutics PLC BRNS|Kezar Life Sciences, Inc - Market Capitalization to Book Value Ratio|SABS: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Akari Therapeutics AKTX|ENLV (Enlivex Therapeutics Ltd.) - Market Value to Book Value|Market Value to Book Value Ratio QTTB|Market Cap to Net Assets Ratio GeoVax Labs|Market Capitalization to Book Value Ratio EDSA|Market Capitalization to Book Value Ratio iBio Corporation IBIO|Market Cap to Net Assets Ratio Carisma Therapeutics Inc.|Market Value to Book Value xtlbio.com XTLB|Market Capitalization to Book Value Ratio BOLT (Bolt Bio)|HCWB: Market Capitalization to Book Value|APVO (aptevotherapeutics.com) - Market Value to Book Value Ratio|AIM (aimimmuno.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio ADTX|Market Cap to Net Assets Ratio gribio.com (GRI)|Market Cap to Net Assets Ratio XRTX|Market Capitalization to Book Value Ratio HIND (Vyome Holdings Inc.)|REVB - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Indaptus Corp INDP|SCNI (Scinai Immunotherapeutics) - Market Capitalization to Book Value Ratio|CALI - Market-to-Book Ratio|AFMD: Market Capitalization to Book Value Ratio|ALLK (Allakos) - Market Capitalization to Book Value Ratio|HOOK - Market Value to Book Value Ratio|Market Value to Book Value IGM Bio|ITOS: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio oceanbiomedical.com (OCEA)|TCBP: Market Capitalization to Book Value Ratio|Third Harmonic Bio Inc. - Market-to-Book Ratio